UY33546A - Corticosteroides para el tratamiento del dolor de las articulaciones - Google Patents
Corticosteroides para el tratamiento del dolor de las articulacionesInfo
- Publication number
- UY33546A UY33546A UY0001033546A UY33546A UY33546A UY 33546 A UY33546 A UY 33546A UY 0001033546 A UY0001033546 A UY 0001033546A UY 33546 A UY33546 A UY 33546A UY 33546 A UY33546 A UY 33546A
- Authority
- UY
- Uruguay
- Prior art keywords
- pain
- caused
- treatment
- osteoarthritis
- rheumatoid arthritis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se proporcionan formulaciones de micropartículas de corticosteroides para el tratamiento del dolor, incluido el dolor causado por enfermedades inflamatorias como, por ejemplo, osteoartritis y artritis reumatoidea, y para enlentecer, detener o revertir el daño tisular estructural causado por enfermedades inflamatorias, por ejemplo daños a los tejidos articulares o peri articular causados por osteoartritis o artritis reumatoidea. Las formulaciones de microparticulas de corticosteroides se administran localmente como una forma de dosificación de liberación sostenida (con o sin un componente de liberación inmediata) que resulta en eficacia acompañada de efectos clínicamente insignificantes o no mensurables sobre la producción de cortisol.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37066610P | 2010-08-04 | 2010-08-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY33546A true UY33546A (es) | 2012-02-29 |
Family
ID=45559826
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001033546A UY33546A (es) | 2010-08-04 | 2011-08-03 | Corticosteroides para el tratamiento del dolor de las articulaciones |
Country Status (23)
Country | Link |
---|---|
US (8) | US20120282298A1 (es) |
EP (2) | EP2600836B1 (es) |
JP (3) | JP5873492B2 (es) |
KR (2) | KR20180132159A (es) |
CN (2) | CN107669640A (es) |
AR (1) | AR082471A1 (es) |
AU (1) | AU2011285691B2 (es) |
BR (1) | BR112013002601A2 (es) |
CA (2) | CA2956556A1 (es) |
CL (1) | CL2013000347A1 (es) |
CO (1) | CO6700827A2 (es) |
ES (1) | ES2799419T3 (es) |
IL (1) | IL224547B (es) |
MX (1) | MX353466B (es) |
MY (1) | MY171929A (es) |
NZ (1) | NZ607797A (es) |
RU (2) | RU2642279C2 (es) |
SG (3) | SG187665A1 (es) |
TW (2) | TWI548412B (es) |
UA (1) | UA111162C2 (es) |
UY (1) | UY33546A (es) |
WO (1) | WO2012019009A1 (es) |
ZA (1) | ZA201300831B (es) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA111162C2 (uk) | 2010-08-04 | 2016-04-11 | Флекшен Терап'Ютікс, Інк. | Ін'єкційна композиція ацетоніду триамцинолону для лікування болю |
ES2855349T3 (es) | 2011-04-25 | 2021-09-23 | Shan Dong Luye Pharm Co Ltd | Composición de risperidona de microesferas de liberación controlada |
CA2843139C (en) * | 2011-08-04 | 2019-09-24 | Flexion Therapeutics, Inc. | Corticosteroids for the treatment of joint pain |
US8927529B2 (en) | 2012-01-30 | 2015-01-06 | SpineThera | Treatment of back pain by injection of microparticles of dexamethasone acetate and a polymer |
EP2948182B1 (en) | 2013-01-23 | 2020-09-30 | Semnur Pharmaceuticals, Inc. | Pharmaceutical formulation comprising an insoluble corticosteroid and a soluble corticosteroid |
ES2697696T3 (es) * | 2013-03-15 | 2019-01-25 | Oakwood Laboratories LLC | Microesferas de liberación sostenida y método de producción de las mismas |
WO2014153384A1 (en) * | 2013-03-19 | 2014-09-25 | Flexion Therapeutics, Inc. | Corticosteroid formulations for the treatment of joint pain and methods of use thereof |
EP3981388A1 (en) * | 2013-03-21 | 2022-04-13 | Eupraxia Pharmaceuticals USA LLC | Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith |
WO2015018461A1 (fr) * | 2013-08-09 | 2015-02-12 | Genbiotech | Compositions therapeutiques comprenant d'acide hyaluronique |
KR20160091960A (ko) * | 2013-11-27 | 2016-08-03 | 에티컨, 엘엘씨 | 정밀하게 제어가능한 흡수 속도를 갖는 흡수성 중합체 블렌드 조성물, 가공 방법, 및 그로부터의 치수 안정한 의료 장치 |
CA2943322C (en) * | 2014-04-08 | 2023-09-19 | Dsm Ip Assets B.V. | Biodegradable polyesteramide used for the treatment of arthritic disorders |
TWI772659B (zh) | 2015-01-21 | 2022-08-01 | 美商桑紐爾製藥公司 | 醫藥配方 |
CN107690333B (zh) * | 2015-06-10 | 2021-12-17 | 赢创运营有限公司 | 制备包含人凝血因子蛋白和乳酸聚合物的粉末的方法 |
CA2998504C (en) | 2015-09-21 | 2023-06-20 | Teva Pharmaceuticals International Gmbh | Sustained release olanzapine formulations |
UY36948A (es) * | 2015-10-13 | 2017-05-31 | Flexion Therapeutics Inc | Formulaciones de corticosteroides para mantener concentraciones de corticosteroide en el líquido sinovial |
PT3206672T (pt) | 2015-10-27 | 2018-06-20 | Eupraxia Pharmaceuticals Inc | Formulações de libertação prolongada de anestésicos locais |
US20170258815A1 (en) * | 2016-03-14 | 2017-09-14 | Flexion Therapeutics, Inc. | Corticosteroid formulations and methods for the treatment of joint pain in patients with diabetes |
WO2018112408A1 (en) * | 2016-12-15 | 2018-06-21 | Flexion Therapeutics, Inc. | Fluticasone formulations and methods of use thereof |
CN106727358A (zh) * | 2017-01-24 | 2017-05-31 | 广州帝奇医药技术有限公司 | 阿立哌唑及其衍生物的缓释组合物与该缓释组合物的制备方法 |
CN106983733A (zh) * | 2017-03-08 | 2017-07-28 | 江苏富泽药业有限公司 | 曲安奈德plga缓释微球注射剂、其制备方法及其在制备治疗骨关节炎疼痛药物中的应用 |
EP3595776A4 (en) * | 2017-03-17 | 2020-09-30 | Flexion Therapeutics, Inc. | FLUTICASONE SUSTAINED-RELEASE FORMULATIONS AND THEIR PROCEDURES FOR USE |
JP2020511483A (ja) | 2017-03-20 | 2020-04-16 | テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーTeva Pharmaceuticals International GmbH | 徐放性オランザピン製剤 |
KR102101969B1 (ko) * | 2017-09-06 | 2020-04-22 | (주)인벤티지랩 | 목시덱틴을 포함하는 마이크로 입자 및 이의 제조 방법 |
US20190336511A1 (en) * | 2018-05-02 | 2019-11-07 | Georgiy Brusovanik | Treatment for Inflammation and Pain with Reduced Gastro-Intestinal Side Effects Combining Methylprednisolone, Paracetamol, and Lansoprazole |
SG11202100054YA (en) * | 2018-07-09 | 2021-02-25 | Taiwan Liposome Co Ltd | Methods to reduce complications of intra-articular steroid |
RU2703257C1 (ru) * | 2018-12-04 | 2019-10-16 | Закрытое акционерное общество "СКАЙ ЛТД" | Способ лечения воспалительных процессов суставов и простатита |
CN109700770B (zh) * | 2019-01-31 | 2021-02-12 | 浙江圣兆药物科技股份有限公司 | 一种曲安奈德微球制剂及其制备方法 |
KR102377975B1 (ko) * | 2019-03-19 | 2022-03-23 | (주)리젠바이오텍 | 스테로이드계 약물을 포함하는 생분해성 고분자 미세입자 및 이의 제조 방법 |
CN112955129A (zh) * | 2019-03-19 | 2021-06-11 | 瑞珍生物科技株式会社 | 包含类固醇类药物的生物降解性高分子微粒及其制备方法 |
WO2020227353A1 (en) * | 2019-05-06 | 2020-11-12 | Fordoz Pharma Corp. | Injectable sustained-release formulations for treatment of joint pain and inflammation |
EP3976106A4 (en) | 2019-05-31 | 2023-01-11 | DOSE Medical Corporation | BIOERODABLE POLYESTER SPINE IMPLANTS AND METHODS OF USE THEREOF |
CN110237052B (zh) * | 2019-07-11 | 2021-07-13 | 苏州大学 | 一种醋酸曲安奈德缓释微球及其制备方法 |
CN111803647A (zh) * | 2020-08-14 | 2020-10-23 | 山东谷雨春生物科技有限公司 | 一种治疗退行性关节炎的药物及其制备方法 |
EP4277661A1 (en) | 2021-01-18 | 2023-11-22 | Anton Frenkel | Pharmaceutical dosage form |
GB202104224D0 (en) | 2021-03-25 | 2021-05-12 | Medincell | Pharmaceutical composition |
AU2022243564A1 (en) * | 2021-03-26 | 2023-09-28 | The Regents Of The University Of California | Immunoregulatory microparticles for modulating inflammatory arthritides |
EP4322923A1 (en) | 2021-04-16 | 2024-02-21 | Fondazione Istituto Italiano di Tecnologia | Polymeric microparticles for the local treatment of chronic inflammatory diseases |
EP4366726A1 (en) | 2021-07-06 | 2024-05-15 | Mark Hasleton | Treatment of serotonin reuptake inhibitor withdrawal syndrome |
WO2024085581A1 (ko) * | 2022-10-17 | 2024-04-25 | (주)인벤티지랩 | 염증성 질환의 치료 또는 예방을 위한 서방형 주사용 조성물 및 이의 제조 방법 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4293539A (en) | 1979-09-12 | 1981-10-06 | Eli Lilly And Company | Controlled release formulations and method of treatment |
US4530840A (en) * | 1982-07-29 | 1985-07-23 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
US5700485A (en) * | 1992-09-10 | 1997-12-23 | Children's Medical Center Corporation | Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid |
CA2172508C (en) | 1993-10-22 | 2005-08-23 | Jeffrey L. Cleland | Method for preparing microspheres comprising a fluidized bed drying step |
EP2283821A1 (en) | 1993-11-19 | 2011-02-16 | Alkermes, Inc. | Preparation of biodegradable microparticles containing a biologically active agent |
JP4272811B2 (ja) | 1997-09-05 | 2009-06-03 | マルホ株式会社 | 関節内疾患治療用のナノカプセル製剤 |
TW577758B (en) * | 1997-10-27 | 2004-03-01 | Ssp Co Ltd | Intra-articular preparation for the treatment of arthropathy |
JPH11222425A (ja) * | 1997-10-27 | 1999-08-17 | Ss Pharmaceut Co Ltd | 関節疾患治療用関節内投与製剤 |
US6726918B1 (en) * | 2000-07-05 | 2004-04-27 | Oculex Pharmaceuticals, Inc. | Methods for treating inflammation-mediated conditions of the eye |
US6824822B2 (en) | 2001-08-31 | 2004-11-30 | Alkermes Controlled Therapeutics Inc. Ii | Residual solvent extraction method and microparticles produced thereby |
JP4062436B2 (ja) | 2000-11-06 | 2008-03-19 | 旭化成ケミカルズ株式会社 | セルロース系製剤用粒子 |
KR100446101B1 (ko) | 2000-12-07 | 2004-08-30 | 주식회사 삼양사 | 수난용성 약물의 서방성 제형 조성물 |
WO2002049620A2 (en) | 2000-12-21 | 2002-06-27 | Inhale Therapeutic Systems, Inc. | Induced phase transition method for the production of microparticles containing hydrophobic active agents |
US20040022853A1 (en) | 2001-04-26 | 2004-02-05 | Control Delivery Systems, Inc. | Polymer-based, sustained release drug delivery system |
WO2004030659A1 (en) * | 2002-09-30 | 2004-04-15 | Acusphere, Inc. | Sustained release porous microparticles for inhalation |
CA2501298A1 (en) | 2002-10-17 | 2004-04-29 | Alkermes Controlled Therapeutics, Inc. | Method of modifying the release profile of sustained release compositions |
EP1605863B1 (en) | 2003-03-14 | 2016-09-07 | Intersect ENT, Inc. | Sinus delivery of sustained release therapeutics |
US20040224030A1 (en) * | 2003-05-06 | 2004-11-11 | Shastri Venkatram R. | Microsphere delivery systems |
MXPA05013340A (es) | 2003-06-09 | 2006-03-09 | Nastech Pharm Co | Composiciones y metodos para liberacion mucosal incrementada de la hormona del crecimiento. |
CA2533887A1 (en) * | 2003-09-30 | 2005-04-14 | Acusphere, Inc. | Injectable, oral, or topical sustained release pharmaceutical formulations |
US7456254B2 (en) * | 2004-04-15 | 2008-11-25 | Alkermes, Inc. | Polymer-based sustained release device |
US8119154B2 (en) * | 2004-04-30 | 2012-02-21 | Allergan, Inc. | Sustained release intraocular implants and related methods |
US20090324678A1 (en) * | 2004-07-16 | 2009-12-31 | Spinal Restoration, Inc. | Methods and kits for treating joints and soft tissues |
US9693967B2 (en) * | 2005-09-07 | 2017-07-04 | Southwest Research Institute | Biodegradable microparticle pharmaceutical formulations exhibiting improved released rates |
JP2009507845A (ja) | 2005-09-07 | 2009-02-26 | サウスウエスト リサーチ インスティテュート | 改良された放出速度を示す生分解性微粒子薬学的処方物 |
US7758778B2 (en) | 2005-09-07 | 2010-07-20 | Southwest Research Institute | Methods for preparing biodegradable microparticle formulations containing pharmaceutically active agents |
US7261529B2 (en) | 2005-09-07 | 2007-08-28 | Southwest Research Institute | Apparatus for preparing biodegradable microparticle formulations containing pharmaceutically active agents |
JP5819579B2 (ja) | 2006-01-13 | 2015-11-24 | サーモディクス,インコーポレイティド | 薬物送達のためのマトリックスを含む微粒子 |
US20070298073A1 (en) * | 2006-06-23 | 2007-12-27 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
CA2663589A1 (en) * | 2006-10-06 | 2008-05-22 | Baxter International Inc. | Microencapsules containing surface-modified microparticles and methods of forming and using the same |
US20080317805A1 (en) * | 2007-06-19 | 2008-12-25 | Mckay William F | Locally administrated low doses of corticosteroids |
US20090105142A1 (en) * | 2007-08-23 | 2009-04-23 | Genzyme Corporation | Treatment with kallikrein inhibitors |
US20110206773A1 (en) | 2008-05-20 | 2011-08-25 | Yale University | Sustained delivery of drugs from biodegradable polymeric microparticles |
CA2727309A1 (en) | 2008-06-09 | 2009-12-17 | Boehringer Ingelheim International Gmbh | Novel embedment particles for inhalation |
EP2331082B1 (en) * | 2008-09-11 | 2021-01-06 | Evonik Corporation | Solvent extraction microencapsulation with tunable extraction rates |
WO2010085609A2 (en) | 2009-01-23 | 2010-07-29 | Surmodics Pharmaceuticals, Inc. | Controlled release systems from polymer blends |
EP2512487A4 (en) | 2009-12-15 | 2013-08-07 | THERAPEUTIC POLYMERNANOPARTICLES WITH CORTICOSTEROIDS AND METHOD FOR THE PRODUCTION AND USE THEREOF | |
UA111162C2 (uk) | 2010-08-04 | 2016-04-11 | Флекшен Терап'Ютікс, Інк. | Ін'єкційна композиція ацетоніду триамцинолону для лікування болю |
-
2011
- 2011-04-08 UA UAA201301676A patent/UA111162C2/uk unknown
- 2011-08-03 AR ARP110102807A patent/AR082471A1/es unknown
- 2011-08-03 UY UY0001033546A patent/UY33546A/es not_active Application Discontinuation
- 2011-08-03 TW TW100127548A patent/TWI548412B/zh active
- 2011-08-03 TW TW105118771A patent/TWI630001B/zh active
- 2011-08-04 JP JP2013523336A patent/JP5873492B2/ja active Active
- 2011-08-04 EP EP11815323.8A patent/EP2600836B1/en active Active
- 2011-08-04 ES ES11815323T patent/ES2799419T3/es active Active
- 2011-08-04 BR BR112013002601A patent/BR112013002601A2/pt not_active Application Discontinuation
- 2011-08-04 CN CN201710992399.XA patent/CN107669640A/zh active Pending
- 2011-08-04 RU RU2013109362A patent/RU2642279C2/ru active
- 2011-08-04 MY MYPI2013000361A patent/MY171929A/en unknown
- 2011-08-04 MX MX2013001433A patent/MX353466B/es active IP Right Grant
- 2011-08-04 RU RU2018100114A patent/RU2018100114A/ru not_active Application Discontinuation
- 2011-08-04 KR KR1020187034479A patent/KR20180132159A/ko not_active Application Discontinuation
- 2011-08-04 AU AU2011285691A patent/AU2011285691B2/en active Active
- 2011-08-04 EP EP20170586.0A patent/EP3701941A1/en not_active Withdrawn
- 2011-08-04 SG SG2013007703A patent/SG187665A1/en unknown
- 2011-08-04 CA CA2956556A patent/CA2956556A1/en not_active Abandoned
- 2011-08-04 SG SG10201607891VA patent/SG10201607891VA/en unknown
- 2011-08-04 KR KR1020137004667A patent/KR101927551B1/ko active IP Right Grant
- 2011-08-04 CN CN201180047943.4A patent/CN103260603B/zh active Active
- 2011-08-04 NZ NZ607797A patent/NZ607797A/en unknown
- 2011-08-04 CA CA2807150A patent/CA2807150C/en active Active
- 2011-08-04 WO PCT/US2011/046601 patent/WO2012019009A1/en active Application Filing
- 2011-08-04 SG SG10201602789XA patent/SG10201602789XA/en unknown
-
2012
- 2012-02-08 US US13/368,580 patent/US20120282298A1/en not_active Abandoned
- 2012-03-16 US US13/422,994 patent/US8828440B2/en active Active
-
2013
- 2013-01-31 ZA ZA2013/00831A patent/ZA201300831B/en unknown
- 2013-02-03 IL IL224547A patent/IL224547B/en active IP Right Grant
- 2013-02-04 CL CL2013000347A patent/CL2013000347A1/es unknown
- 2013-03-04 CO CO13043214A patent/CO6700827A2/es unknown
- 2013-12-16 US US14/107,188 patent/US20140242170A1/en not_active Abandoned
-
2014
- 2014-08-18 US US14/461,883 patent/US9555047B2/en active Active
- 2014-08-18 US US14/461,884 patent/US9555048B2/en active Active
-
2015
- 2015-09-09 JP JP2015177143A patent/JP2016028070A/ja not_active Ceased
-
2017
- 2017-01-31 US US15/420,829 patent/US20170135957A1/en not_active Abandoned
- 2017-03-15 US US15/459,961 patent/US9949987B2/en active Active
-
2018
- 2018-03-27 US US15/937,053 patent/US10624905B2/en active Active
- 2018-11-29 JP JP2018223009A patent/JP2019059752A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY33546A (es) | Corticosteroides para el tratamiento del dolor de las articulaciones | |
CL2019000431A1 (es) | Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos. (divisional solicitud 201700814) | |
UY32989A (es) | Coposiciones terapéuticas concentradas de fosfolípidos | |
GT200600297A (es) | Nuevos anticuerpos anti-madcam | |
CL2013000063A1 (es) | Un método para tratar a un sujeto que comprende administrar n-etil-n-fenil1,2-dihidroxi-4-hodroxi-5-cloro-1-metil-2-oxoquinolina-3-carboxamida opcionalmente deuterada, para el tratamiento de una enfermedad autoinmunitaria; una mezcla de los mismos; composición farmaceutica y su proceso de preparacion. | |
CO6531427A2 (es) | Composiciones de corticosteriodes administradas oralmente | |
BR112015020389A8 (pt) | compostos carbazol úteis como inibidores de bromodomínio, seu uso, bem como composição e produto farmacêuticos compreendendo os mesmos | |
UY33029A (es) | Antagonistas de espiro-oxindol de mdm2 | |
CO6771417A2 (es) | Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis | |
GT201400069A (es) | Composiciones farmaceuticas | |
PE20180399A1 (es) | Composiciones transdermicas de ibuprofeno y metodos de uso de las mismas | |
CL2008002999A1 (es) | Uso de una composicion farmeceutica que comprende trns-clominefo para preparar un medicamenteo util en el ratamiento de recuccion de los niveles de glucosa en ayunas en un varon. | |
CO6491060A2 (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
BR112014020271A8 (pt) | Composição farmacêutica e métodos para diminuir a frequência de micção em paciente | |
CY1122113T1 (el) | Φαρμακευτικες συνθεσεις για τη θεραπεια του ελικοβακτηριδιου του πυλωρου | |
CO6710926A2 (es) | Compuestos de n-heteroarilo | |
BR112017016087A2 (pt) | formulações para coxim articular adiposo e métodos de uso das mesmas | |
CO7141430A2 (es) | Formulaciones vesiculares para uso en el tratamiento del dolor o movilidad reducida de una articulación | |
WO2014107730A3 (en) | Use of fatty acid niacin conjugates for treating diseases | |
CO2019008053A2 (es) | Agente terapéutico para enfermedades del hígado | |
BR112015029894A2 (pt) | forma de dosagem farmacêutica sólida | |
BR112015001627A2 (pt) | composição farmacêutica, respectivos usos e método para diminuir a frequência de micção | |
AR083095A1 (es) | Cocristal de aprepitant l-prolina y composicion farmaceutica | |
NI201200196A (es) | Agentes terapéuticos 976 | |
CL2016002655A1 (es) | Composición farmacéutica para el tratamiento de alopatías relacionadas con el dolor, usando como agente activo al ketorolaco trometamina y clorhidrato de tramadol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20200820 |